Cargando…

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy

The anti-CD20-specific monoclonal antibody rituximab (RTX), in combination with chemotherapy, is commonly used for primary treatment in chronic lymphocytic leukemia (CLL). However, relapses remain important and activation of the complement pathway is one of the mechanisms by which RTX generates the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bordron, Anne, Bagacean, Cristina, Mohr, Audrey, Tempescul, Adrian, Bendaoud, Boutahar, Deshayes, Stéphanie, Dalbies, Florence, Buors, Caroline, Saad, Hussam, Berthou, Christian, Pers, Jacques-Olivier, Renaudineau, Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114972/ https://www.ncbi.nlm.nih.gov/pubmed/30167081 http://dx.doi.org/10.18632/oncotarget.25657

Ejemplares similares

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2019)

Rapid and complete response to idelalisib in a case of Richter syndrome
por: Bagacean, Cristina, et al.
Publicado: (2019)

Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion
por: Bagacean, Cristina, et al.
Publicado: (2017)

Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2017)

Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis
por: Seret, Guillaume, et al.
Publicado: (2013)

DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag
por: Bagacean, Cristina, et al.
Publicado: (2017)

ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases
por: Ungur, Rodica, et al.
Publicado: (2015)

Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities
por: Rodrigues, Emily, et al.
Publicado: (2018)

STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia
por: Debant, Marjolaine, et al.
Publicado: (2019)

Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases
por: Alonso-Ramirez, Ruby, et al.
Publicado: (2010)

Exopolysaccharides Isolated from Hydrothermal Vent Bacteria Can Modulate the Complement System
por: Courtois, Anthony, et al.
Publicado: (2014)

A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency
por: Hammadi, Mariam, et al.
Publicado: (2010)

Floridoside Extracted from the Red Alga Mastocarpus stellatus Is a Potent Activator of the Classical Complement Pathway
por: Courtois, Anthony, et al.
Publicado: (2008)

Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases
por: Bordron, Anne, et al.
Publicado: (2021)

Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype
por: Beatson, Richard, et al.
Publicado: (2020)

C-Myc-induced hypersialylation of small cell lung cancer facilitates pro-tumoral phenotypes of macrophages
por: Tian, Lin, et al.
Publicado: (2023)

BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance
por: Shu, Xiaodong, et al.
Publicado: (2023)

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
por: Daly, John, et al.
Publicado: (2022)

The fragility index in 2010-2021 chronic lymphocytic leukemia randomized controlled trials
por: Bagacean, Cristina, et al.
Publicado: (2022)

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)
por: Le Calloch, Ronan, et al.
Publicado: (2018)

Simulated patient and role play methodologies for communication skills and empathy training of undergraduate medical students
por: Bagacean, Cristina, et al.
Publicado: (2020)

Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report
por: Bagacean, Cristina, et al.
Publicado: (2016)

Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
por: Morel, Marie, et al.
Publicado: (2022)

Hemorrhagic Cystitis due to BK Reactivation in a Young Female Treated for Hodgkin-Disease
por: Le Calloch, R., et al.
Publicado: (2011)

Ultrasound assessment of salivary glands in patients with primary Sjögren’s syndrome treated with rituximab: Quantitative and Doppler waveform analysis
por: Jousse-Joulin, Sandrine, et al.
Publicado: (2007)

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1
por: Stirnemann, Jérôme, et al.
Publicado: (2015)

JAK Inhibitors and Oxidative Stress Control
por: Charras, Amandine, et al.
Publicado: (2019)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
por: Zinzani, P. L., et al.
Publicado: (2022)

Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis
por: Duroux-Richard, Isabelle, et al.
Publicado: (2014)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

An in silico Approach Reveals Associations between Genetic and Epigenetic Factors within Regulatory Elements in B Cells from Primary Sjögren’s Syndrome Patients
por: Konsta, Orsia D., et al.
Publicado: (2015)

Infection by H1N1 flu virus revealing T-cell acute lymphoid leukaemia: about two cases
por: Lefevre, Guillaume, et al.
Publicado: (2010)

Exudative pericarditis in the evolution of a diffuse large B-cell lymphoma
por: Bagacean, Cristina, et al.
Publicado: (2015)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Metabolic Program of Regulatory B Lymphocytes and Influence in the Control of Malignant and Autoimmune Situations
por: Iperi, Cristian, et al.
Publicado: (2021)

A case of IgE myeloma transformed into IgE-producing plasma cell leukaemia
por: Galakhoff, Nicolas, et al.
Publicado: (2019)

MicroRNAs Associated With a Good Prognosis of Acute Myeloid Leukemia and Their Effect on Macrophage Polarization
por: Neaga, Alexandra, et al.
Publicado: (2021)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity
por: Hörl, S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6erhlqu5466hocl7r5bpmnbalq